
HiberCell: A pioneering drug development company focused on combating metastatic cancer.
HiberCell is a pioneering drug development company dedicated to combating metastatic cancer. As the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy, HiberCell aims to address the significant challenge of treatment resistance, cancer relapse, and metastasis. Their innovative approach targets adaptive stress mechanisms in tumors, striving to develop differentiated treatments that enable patients to live longer, healthier lives.
HiberCell has made significant strides in the field of oncology by focusing on novel therapeutic strategies that address the root causes of cancer persistence and recurrence. Their work has garnered attention for its potential to transform cancer treatment paradigms and improve patient outcomes. By leveraging cutting-edge research and development, HiberCell continues to push the boundaries of cancer therapy, making a profound impact on the lives of those affected by metastatic cancer.

HebeCell
hebecellcorp.com

Cellvie
cellvie.bio

Hibernaid

Cellevolve Bio
cellevolve.com

ExpressCells

Cell BioEngines
cellbioengines.com

Cellular Approaches

MelliCell
mellicell.com

Cellworks

Cell Care Therapeutics
cell-care.com

SymbioCellTech
symbiocelltech.com

Celltheon
celltheon.com

Empiri
empiricancer.com

Cellular Engineering Technologies
celleng-tech.com

CellVax Therapeutics
cellvx.com
Companies similar to HiberCell include HebeCell, Cellvie, Hibernaid and Cellevolve Bio.
HiberCell was founded in 2019.
HiberCell's headquarters is located in New York City, NY, US.
HiberCell's most recent funding round was for $30M (USD) in May 2021.
As of May 19, 2021, HiberCell has raised a total of $158.2M (USD).
HiberCell has 87 employees as of Feb 4, 2024.